Selective Therapy of Neuroblastoma

神经母细胞瘤的选择性治疗

• 批准号: 6740934
• 负责人: MARY K DANKS
• 金额: $ 22.5万
• 依托单位: ST. JUDE CHILDREN'S RESEARCH HOSPITAL
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-07-09 至 2008-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6740934
• 关键词: Adenoviridae; DNA topoisomerases; bone marrow purging; carboxylic ester hydrolases; clinical research; clinical trials; cytotoxicity; drug delivery systems; drug screening /evaluation; enzyme activity; enzyme inhibitors; gene expression; genetic promoter element; genetic transcription; human subject; laboratory mouse; metastasis; neoplasm /cancer chemotherapy; neuroblastoma; pediatric neoplasm /cancer; polymerase chain reaction; prodrugs; protein structure function; transcription factor; transfection /expression vector

DESCRIPTION (provided by applicant): Neuroblastoma (NB) is the most common extracranial solid tumor in pediatric patients. Treatment for high-risk patients includes surgery and high dose chemotherapy with autologous stem cell rescue. However, in spite of aggressive therapy, up to 80% of patients relapse and die of disseminated disease. Therefore, novel approaches to the treatment of NB are necessary. One potential approach is viral-directed enzyme prodrug therapy (VDEPT), using adenoviruses to deliver cDNAs encoding carboxylesterases (CEs) that efficiently activate the prodrug CPT-11. This drug has shown encouraging activity in NB patients, but is activated inefficiently in vivo. Work during the previous funding cycle documented that rabbit liver CE/CPT-11 VDEPT sensitizes primary NB cells to CPT-11, and can be used to purge NB cells from human hematopoietic "stem" cells without toxicity to progenitor cells or CD34+ NOD/SCID repopulating cells. In the next funding cycle, we propose to complete an ongoing nontherapeutic clinical trial for purging bone marrow specimens containing >1% tumor cells, and to identify appropriate CEs to make CE/CPT-11 VDEPT useful for in vivo application. Specific Aims include: 1) completion of the ongoing clinical trial; 2) modification of a human enzyme to produce an efficient CPT-11 activating enzyme with minimal immunogenicity; and 3) to achieve tumor-specific toxicity in mouse models of NB by using tumor specific promoters and replication-selective adenoviral vectors to deliver CE cDNA. Overall, these studies should provide alternative treatment modalities for high-risk neuroblastoma.

描述（由申请方提供）：神经母细胞瘤（NB）是儿科患者中最常见的颅外实体瘤。高风险患者的治疗包括手术和高剂量化疗与自体干细胞挽救。然而，尽管有积极的治疗，高达80%的患者复发并死于播散性疾病。因此，治疗NB的新方法是必要的。一种潜在的方法是病毒导向的酶前体药物治疗（VDEPT），使用腺病毒递送编码羧酸酯酶（CE）的cDNA，其有效地激活前体药物CPT-11。这种药物在NB患者中显示出令人鼓舞的活性，但在体内活化效率低。在前一个资助周期期间的工作记录了兔肝CE/CPT-11 VDEPT使原代NB细胞对CPT-11敏感，并且可以用于从人造血“干”细胞中清除NB细胞，而对祖细胞或CD 34 + NOD/SCID再增殖细胞没有毒性。在下一个资助周期中，我们计划完成一项正在进行的非治疗性临床试验，用于清除含有>1%肿瘤细胞的骨髓标本，并确定适当的CE，使CE/CPT-11 VDEPT可用于体内应用。具体目标包括：1）完成正在进行的临床试验; 2）修饰人酶以产生具有最小免疫原性的有效CPT-11活化酶;和3）通过使用肿瘤特异性启动子和复制选择性腺病毒载体递送CE cDNA来在NB小鼠模型中实现肿瘤特异性毒性。总的来说，这些研究应该为高危神经母细胞瘤提供替代治疗方式。